DCM
VRTX icon

DAFNA Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

DAFNA Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-8,600
Closed -$689K – 56
2013
Q2 		$689K Buy
+8,600
New +$633K 1.01% 28

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DAFNA Capital Management's VRTX Position: Q3 2013 in Review

DAFNA Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2013, closing a stake of 8,600 shares — an estimated $689K sold.

DAFNA Capital Management first reported a position in VRTX in Q2 2013 and held it in 1 quarter. The position peaked at $689K in Q2 2013. 403 funds tracked by Wall St. Rank hold VRTX as of Q3 2013.

  • DAFNA Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • DAFNA Capital Management sold 8,600 Vertex Pharmaceuticals shares in Q3 2013, an estimated $689K.
  • DAFNA Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • DAFNA Capital Management's Vertex Pharmaceuticals position peaked at $689K in Q2 2013.
  • 403 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2013.

Based on DAFNA Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.